ArticleScience translational medicine2015

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

David Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.